Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Closure70on Dec 17, 2020 10:13pm
118 Views
Post# 32137477

RE:RE:RE:RE:RE:RE:RE:RE:Dr, Mark Williams ??

RE:RE:RE:RE:RE:RE:RE:RE:Dr, Mark Williams ??This may not be a popular reply but having someone work for multiple companies is not unusual.
Consultants do it all the time, they have contracts (just like management contracts)  with either standard or creative success based compensation.  Typically, as long as there can be demonstrated that there isn't a conflic of interest, all is good.  

I agree that since both company's are in the same space, or percieed to be, they shoudl make some form of comment now that it was announced.  Lets face it, once this takes off, they will have more than enough money thrown at them to staff up to have Williams provide his expertise   and exoperience to direction. 

I do like the comment that was made today, those who are investors in the company think feel comfortable with where it will go.  Thos playong the stock are understandably dissapointed, I just never got or will get why anyone in their right mind would stick around a board and piss all over the company or the investment...why waste your time ?? unless you have a reaso to do so...

GLTA


<< Previous
Bullboard Posts
Next >>